Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tommy Dooley

Physician Assistant Barboursville, WV Physician Assistant

NPI 1740709138 CMS profile 10527810

6007 US Rt 60 E Suite 130, Barboursville, WV 25504

Open in the dashboard

General payments

$7,455

396 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tommy Dooley of Barboursville, WV is reported in the CMS Open Payments database as having received $7,455 across 396 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,735 98
2024 General $1,928 100
2023 General $994 64
2022 General $838 39
2021 General $1,959 95

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tommy Dooley
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tommy Dooley were reported at $1,735. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tommy Dooley Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,959 $132 $37–$438 $132
2022 $838 $155 $48–$522 $149
2023 $994 $167 $52–$557 $160
2024 $1,928 $178 $55–$600 $164
2025 $1,735 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,003 123 payments
  2. Janssen Biotech, Inc. $1,150 64 payments
  3. Regeneron Healthcare Solutions, Inc. $1,030 38 payments
  4. Sun Pharmaceutical Industries Inc. $683 26 payments
  5. E.R. Squibb & Sons, L.L.C. $420 30 payments
  6. Lilly USA, LLC $369 20 payments
  7. UCB, Inc. $294 21 payments
  8. Novartis Pharmaceuticals Corporation $271 16 payments
  9. Pfizer Inc. $197 10 payments
  10. Galderma Laboratories, L.P. $176 8 payments
  11. Other $862 40 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,685 384 payments
  2. Education $770 12 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,038 57 payments
  2. SKYRIZI Immunology $810 46 payments
  3. RINVOQ $734 50 payments
  4. DUPIXENT Inflammation And Immunology $726 27 payments
  5. ILUMYA $483 22 payments
  6. SOTYKTU $420 30 payments
  7. DUPIXENT Immunology $337 7 payments
  8. TALTZ $317 18 payments
  9. DUPIXENT Immunology And Inflammation $304 11 payments
  10. SKYRIZI Immunology $302 20 payments
  11. Other $2,384 138 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,773

Median for Physician Assistant: 241

Drug cost

$948,988

Median for Physician Assistant: $4,110

Branded share of claims

13.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 89 $327,622
Tremfya Guselkumab Brand 15 $228,693
Taltz Autoinjector Ixekizumab Brand 19 $159,504
Cosentyx Sensoready (2 Pens) Secukinumab Brand 14 $119,769
Otezla Apremilast Brand 13 $62,205
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 15 $9,449
Clobetasol Propionate Generic 168 $7,442
Fluorouracil Generic 91 $6,194
Metronidazole Generic 54 $5,613
Doxycycline Hyclate Generic 247 $3,171

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$91,735

Medicare's payments for the services billed

Medicare patients

437

Average age 73

Services billed

2,478

233 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 30%
Ischemic heart disease 23%
Chronic kidney disease 21%
Depression 18%
Atrial fibrillation 15%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $464
$464 15 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $273
$273 89 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $222
$222 — —
RINVOQ
  • AbbVie, Inc. $193
$193 — —
SKYRIZI
  • AbbVie, Inc. $120
$120 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

396 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record